Predicting Malignant Mesothelioma by Analyzing Serum N-ERC/Mesothelin, C-ERC/Mesothelin, Hyaluronan, Osteopontin, and Syndecan-1 Levels
EURASIAN JOURNAL OF PULMONOLOGY, cilt.19, sa.3, ss.130-138, 2017 (ESCI, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 19 Sayı: 3
- Basım Tarihi: 2017
- Doi Numarası: 10.5152/ejp.2017.50023
- Dergi Adı: EURASIAN JOURNAL OF PULMONOLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.130-138
- Anahtar Kelimeler: Hyaluronan, megakaryocyte potentiating factor, mesothelin, mesothelioma, osteopontin, syndecan-1, MEGAKARYOCYTE POTENTIATING FACTOR, PLEURAL MESOTHELIOMA, SOLUBLE MESOTHELIN, TUMOR-MARKER, TRIMODALITY TREATMENT, FAMILY PROTEINS, LUNG-CANCER, DIAGNOSIS, ASBESTOS, BIOMARKERS
- Eskişehir Osmangazi Üniversitesi Adresli: Evet
Özet
Objective: Tumor biomarkers are promising study areas for the early or differential diagnosis of malignant pleural mesothelioma (MPM). This study aimed to determine the effectiveness of analyzing serum N-ERC/mesothelin, C-ERC/mesothelin, hyaluronan, osteopontin, and syndecan-1 levels for distinguishing patients with MPM from those with metastatic malignant pleural diseases (MMPDs), benign pleural diseases (BPDs), and benign asbestos pleurisy (BAP).